Home › Oral Cancer › Florida › Tampa
Oral Cancer clinical trials in Tampa, FL
3 studies for Oral Cancer are looking for participants at sites in and around Tampa (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer
RecruitingPhase 1
- Moffitt Cancer Center, Tampa
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
RecruitingPhase 2
- Moffitt Cancer Center-International Plaza, Tampa
- Moffitt Cancer Center - McKinley Campus, Tampa
- Moffitt Cancer Center, Tampa
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
RecruitingPhase 2
- Moffitt Cancer Center-International Plaza, Tampa
- Moffitt Cancer Center - McKinley Campus, Tampa
- Moffitt Cancer Center, Tampa
About Oral Cancer
Oral cancer can form in the mouth or throat but usually begins in the tongue and floor of the mouth. Read about the common oral cancer symptoms.
More about Oral Cancer on MedlinePlus
Oral Cancer trials in other cities
- Atlanta, GA9 studies
- St. Louis, MO8 studies
- Chicago, IL8 studies
- New York City, NY8 studies
- Durham, NC7 studies
- Houston, TX7 studies
- Kansas City, MO7 studies
- Milwaukee, WI7 studies
- Portland, OR7 studies
- Pittsburgh, PA7 studies
- Ann Arbor, MI7 studies
- Richmond, VA7 studies
Other studies in Tampa
- Non-Small Cell Lung Cancer51 studies
- Breast Cancer43 studies
- Cancer (all types)39 studies
- Colorectal Cancer34 studies
- Acute Myeloid Leukemia29 studies
- Metastatic Cancer29 studies
- Lung Cancer29 studies
- Pancreatic Cancer26 studies
- Ovarian Cancer21 studies
- Melanoma19 studies
- Myelodysplastic Syndromes19 studies
- Prostate Cancer18 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.